Antirobe vet.

8 x 10 pc

Capsule, hard

Active substance

Clindamycin (Clindamycin hydrochloride) : 25 mg

ATC code

QJ01FF01 Clindamycin

QJ01FF Lincosamides

QJ01F Macrolides, lincosamides and streptogramins

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Dogs and cats.

Indications

Antirobe Capsules 25 mg are indicated for use in dogs and cats as follows:

Dogs: For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with Staphylococcus spp., Streptococcus spp. (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum, and Clostridium perfringens. To help provide antimicrobial cover during dental procedures.

For the treatment of superficial pyoderma associated with Staphylococcus intermedius.

For the treatment of osteomyelitis, caused by Staphylococcus aureus.

Cats: For the treatment of infected wounds and abscesses and infected mouth cavity and dental infections, caused by bacteria sensitive to clindamycin. To help provide antimicrobial cover during dental procedures.

Before Antirobe therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.

Dose to be administered and administration route

For oral administration only.

1. For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections in dogs and cats, administer either:

• 5.5 mg/kg of bodyweight every 12 hours for 7-10 days, or

• 11 mg/kg of bodyweight every 24 hours for 7-10 days

If no clinical response is seen within 4 days, redetermine the diagnosis. To help provide antimicrobial cover during dental procedures, a 10 day course is recommended. This should be initiated five days before dental therapy and continued for five days thereafter. In dogs, treatment may be extended to a maximum of 28 days based on clinical judgement.

2. For the treatment of superficial pyoderma in dogs, administer either:

• 5.5 mg/kg of bodyweight every 12 hours, or

• 11 mg/kg of bodyweight every 24 hours

Therapy of canine superficial pyoderma is usually recommended for 21 days, with extension of therapy based on clinical judgement.

3. For the treatment of osteomyelitis in dogs, administer:

• 11 mg/kg of bodyweight every 12 hours for a minimum of 28 days

If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.

Adverse reactions

Vomiting and diarrhoea have occasionally been observed.

Antirobe sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.